Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose beta-epoietin for kidney transplant outcomes
NCT01450878Phase 3Terminated
- Sponsor
- CHU de Limoges
- Start
- Dec 2011
- Primary completion
- Mar 2013
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epoetin beta in ischemia-reperfusion injury (IRI), sponsored by CHU de Limoges. Primary endpoint: Plasma creatinine level at 5 days. Started Dec 2011; status: terminated.
02
Drugs
epoetin beta
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01450878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450878.